{"id":526346,"date":"2021-01-14T14:44:02","date_gmt":"2021-01-14T14:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=526346"},"modified":"2021-01-14T14:44:02","modified_gmt":"2021-01-14T14:44:02","slug":"myelodysplastic-syndrome-market-size-share-trends-growth-key-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myelodysplastic-syndrome-market-size-share-trends-growth-key-companies-emerging-drugs-and-epidemiology-forecast_526346.html","title":{"rendered":"Myelodysplastic Syndrome Market Size, Share, Trends, Growth, Key Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Myelodysplastic<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Myelodysplastic syndrome (MDS)<\/strong> constitute a group of clonal myeloid neoplasms characterized by anaemia or other cytopenias due to ineffective hematopoiesis, abnormal blood, and bone marrow cell morphology, as well as, the risk for clonal evolution and progression to acute myeloid leukaemia (AML).<\/p>\n

Some patients have Myelodysplastic Syndrome cells in their bone marrow even after the treatment, and this condition is called refractory MDS. While some patients have a return of MDS cells in the marrow and a decrease in normal blood cells after remission, which is called a relapse. Patients with Myelodysplastic Syndrome collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML. Refractory Myelodysplastic Syndrome is typically treated with a different treatment than the first therapy used, and relapsed MDS is typically treated with either the same treatment used before or a different standard treatment. No standard exists for the treatment of MDS relapsing after allogeneic stem cell transplantation.<\/p>\n

Get FREE sample copy at: 
https:\/\/www.delveinsight.com\/sample-request\/myelodysplastic-syndrome-market<\/a>
<\/strong><\/p>\n

 <\/p>\n

The Myelodysplastic Syndrome market report also covers emerging drugs, current treatment practices, Myelodysplastic Syndrome market size and share of the individual therapies, current and forecasted Myelodysplastic Syndrome Market Size from 2017 to 2030 segmented by seven major markets.<\/p>\n

The report provides a detailed current Myelodysplastic Syndrome treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Myelodysplastic<\/p>\n

 Myelodysplastic Syndrome Market Key Facts<\/strong><\/p>\n

According to population-based registry data (1993–2008) analysis in Japan, the incidence of MDS<\/strong> sharply increased with age, particularly in those over age 70 years. The incidence in 65–69 years was reported to be 3.1 cases\/100,000 (men) and 1.1 cases\/100,000 (women), in comparison to 85 years in which the rate was 17.7 and 8.9 cases\/100,000, respectively<\/p>\n

According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Myelodysplastic Syndrome (MDS).<\/strong><\/p>\n

In MDS-RS, a minimum of 15% of the early red blood cells must be ring sideroblast with a mutation in the SF3B1 gene. It can be divided into two categories (MDS-RS-SLD, MDS-RS-MLD) and rarely turns into AML.<\/p>\n

 <\/p>\n

Key Benefits of Myelodysplastic Syndrome Market Report<\/strong><\/p>\n